GSK126 (Synonyms: EZH2 inhibitor;GSK-126;GSK 126) |
| Catalog No.GC15783 |
선택적인 EZH2 억제제
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1346574-57-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
GSK126 (GSK2816126A, GSK2816126) is a highly selective EZH2 methyltransferase inhibitor with IC50 12.6-17.4nM in vitro (MM cells), and IC50 9.9nM in vivo (Male *ApoE-/-* mice) [1,2]. Published researches show that targeting EZH2 by GSK126 is beneficial to reduces atherosclerotic plaque, and suppresses carcinogenesis, cell migration, and angiogenesis[3].
In vitro, GSK126 (5µM; 36h; 37˚C) pharmacologically inhibits EZH2, reduces lipid transportation and monocyte adhesion during atherogenesis by increasing the expression levels of ATP-binding cassette transporter A1 and suppressing vascular cell adhesion molecule 1 in human THP-1 cells[2]. GSK126 (5, 10μM; 48h) suppress colorectal cancer by regulating macrophage polarization in the tumor microenvironment in a MC38 and RAW264.7 cells based 3D culture model[4]. GSK126 (1nM-10μM; 7 days) suppress HTLV-1-infected CD4+ T cell proliferation and hyperimmune response in HTLV-1-associated myelopathy[5].
In vivo, GSK126-treated(50mg/kg/day; 10 weeks; i.p) mice showed significantly decreased atherosclerotic plaques[2]. GSK126 (100mg/kg; 1 month; i.p) inhibits the growth of colorectal cancer cells/xenografts in BALB/c nu/nu model[6]. GSK126(1nM-100μM; 3 times a week; i.p) enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer C57BL/6 mice model[7].
References:
[1] Zeng, Delong et al. “Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.” *Oncotarget* vol. 8,2 (2017): 3396-3411. doi:10.18632/oncotarget.13773
[2] Wei, Xianjing et al. “Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E-deficient mice.” *Experimental and therapeutic medicine*vol. 22,2 (2021): 841. doi:10.3892/etm.2021.10273
[3] Chen, Ya-Tian et al. “The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A.” *Cancer chemotherapy and pharmacology* vol. 77,4 (2016): 757-65. doi:10.1007/s00280-016-2990-1
[4] Li, Chen et al. “EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.” *Frontiers in immunology* vol. 13 857808. 1 Apr. 2022, doi:10.3389/fimmu.2022.857808
[5] Koseki, Akihito et al. “EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy.” *Frontiers in microbiology* vol. 14 1175762. 12 Jun. 2023, doi:10.3389/fmicb.2023.1175762
[6] Yang, Liu et al. “PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.” *Theranostics* vol. 11,8 3742-3759. 27 Jan. 2021, doi:10.7150/thno.53023
[7]Zhou, Liye et al. “Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,1 (2020): 290-300. doi:10.1158/1078-0432.CCR-19-1351
| Cell experiment [1]: | |
Cell lines | human THP-1 cells |
Preparation Method | THP-1 cells were cultured in RPMI-1640 medium and treated with PMA for 48h. Subsequently, the cells were treated with GSK126 (5µM) for 36h at 37˚C in a CO2 incubator. THP-1 macrophages were then washed with PBS and cultured in serum-free RPMI-1640 medium. Following overnight fasting, the macrophages were washed with PBS again and cultured in medium with or without Ox-LDL (100µg/ml) for 48h. After incubation, macrophages were fixed in methanol at room temperature for 30min and stained with Oil Red O for 20min at room temperature and observed under a DP80 fluorescent microscope at x200 magnification. Experiments were repeated in triplicate in each group. |
Reaction Conditions | 5µM; 36h; 37˚C |
Applications | In vitro, it was found that pharmacological inhibition of EZH2 by GSK126 markedly reduced lipid transportation and monocyte adhesion during atherogenesis, predominantly through increasing the expression levels of ATP-binding cassette transporter A1 and suppressing vascular cell adhesion molecule 1 in human THP-1 cells. |
| Animal experiment [1]: | |
Animal models | Male ApoE-/- mice (n=18; age, 6-8 weeks; weight ~20g) |
Preparation Method | Male ApoE-/- mice were maintained under a specific pathogen-free environment in microisolator cages. The mice were separated into the control group (chow diet + DMSO/PBS injection), vehicle group (high-fat diet + DMSO/PBS injection) and treatment group (high-fat diet + GSK126 treatment), with six mice in each group. The mice in the control group were fed a chow diet, whereas the mice in the vehicle and treatment groups were fed a high-fat diet (21% fat, 0.15% cholesterol). All animals had free access to foods. In addition, the mice in the treatment group received a daily intraperitoneal injection of GSK126 at a dose of 50mg/kg/day (mouse body weight) for 10 weeks. The mice in the vehicle group were administered a daily intraperitoneal injection of 20% DMSO/PBS (volume, 0.1ml). Animals were sacrificed at 16-18 weeks of age. CO2 was supplied in a precisely regulated and purified form. Flow meter was used in order to maintain a gradual fill/displacement rate of 10-30% of chamber volume per min. CO2 flow was maintained for at least 1min after respiratory arrest. Following sacrifice by inhalation of CO2, the animals' heart tissue samples were collected, embedded in the OCT gel without fixation and stored at -80˚C immediately. |
Dosage form | 50mg/kg/day; 10 weeks; i.p |
Applications | In vivo, it was found that atherosclerotic plaques in GSK126-treated mice were significantly decreased when comparing with the vehicle-treated animals. These results indicated that the GSK126 has the ability to attenuate the progression of atherosclerosis by reducing macrophage foam cell formation and monocyte adhesion in cell and mouse models. |
References: | |
| Cas No. | 1346574-57-9 | SDF | |
| Synonyms | EZH2 inhibitor;GSK-126;GSK 126 | ||
| Chemical Name | 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide | ||
| Canonical SMILES | CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C | ||
| Formula | C31H38N6O2 | M.Wt | 526.67 |
| Solubility | ≥ 3.29 mg/mL in DMSO, <2.4 mg/mL in EtOH, <2.27 mg/mL in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8987 mL | 9.4936 mL | 18.9872 mL |
| 5 mM | 0.3797 mL | 1.8987 mL | 3.7974 mL |
| 10 mM | 0.1899 mL | 0.9494 mL | 1.8987 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *